HIV cocktail aims to free patients from daily pills
NCT ID NCT06805656
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a mix of intensified antiretrovirals, a latency-reversing drug, an anti-proliferative drug, and a personalized vaccine can shrink the hidden HIV reservoir enough to allow people to stop their daily medication. The study will enroll 70 adults with well-controlled HIV. Researchers will monitor viral rebound and immune responses during a treatment interruption.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Maraviroc, Dolutegravir, Auranofin, Nicotinamide, and a personalized dendritic cell vaccine
What this could lead to
If successful, this could point toward a way for people with HIV to stay healthy without needing daily antiretroviral pills.
What could go wrong
This is a small, early-phase trial (70 people) and previous attempts at HIV remission have failed. The combination approach is complex and may not work for everyone, or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CCDI
São Paulo, São Paulo, Brazil
Contact